Positive Airway Pressure Therapies and Oxygen Therapy in Obstructive Sleep Apnea (OSA): 5-Year Survival
by
, , , ,
Juan Sebastian Hernández Puentes
1
,
Alirio Rodrigo Bastidas
1,2,3,*,
Eduardo Andres Tuta Quintero
1,2,4,
Juan David Acosta Otero
1,
Valeria Leyton Franco
1,
Juan Diego Castro Córdoba
1,
Lina María López Nuñez
1,
Isabella Lenhardt Guaqueta
1,
Alejandra Mora Vega
1,
Paola Stefanny Martínez Sáenz
1,
Charbel Kamil Faizal Gomez
4,
María Catalina Vaca Espinosa
2,
Cristian Felipe Cardona Molina
2,
Gabriela Diaz Romero
1 and
Avril Johanna Rubio Noel
1 1
School of Medicine, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía 250001, Colombia
2
Internal Medicine, Universidad de La Sabana, Chía 170001, Colombia
3
Clinical Medicine Applied Research Group, Universidad de La Sabana, Chía 170001, Colombia
4
Epidemiology, Universidad de La Sabana, Chía 250001, Colombia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(24), 8647; https://doi.org/10.3390/jcm14248647
Submission received: 25 September 2025
/
Revised: 6 November 2025
/
Accepted: 11 November 2025
/
Published: 6 December 2025
(This article belongs to the Special Issue Advanced Strategy for Diagnosis and Treatment of Obstructive Sleep Apnea Syndrome (OSAS))
Abstract
Background: Obstructive sleep apnea (OSA) is a highly prevalent disorder associated with increased morbidity and mortality. Continuous positive airway pressure (CPAP) remains the first-line therapy, but its long-term effectiveness is limited by suboptimal adherence, with only 50–60% of patients achieving the recommended use. Evidence on adherence with alternative modalities, such as bilevel positive airway pressure (BiPAP) or oxygen therapy, is even more limited. Furthermore, few studies have directly compared these treatments with each other, particularly in relation to survival outcomes. Objective: Evaluate 5-year survival in patients with OSA treated with CPAP, BIPAP, or oxygen therapy. Methods: A retrospective cohort study with survival analysis was conducted in subjects with OSA followed at a tertiary-level institution in Colombia between January 2005 and December 2021. Results: Among 3039 patients with OSA (mean age 59.6 years; 59.8% male), the five-year mortality rate was 5.8%. Deceased patients presented a higher prevalence of comorbidities, including hypertension, diabetes, and cardiovascular disease (all p < 0.001). Adherence to CPAP was significantly lower in deceased patients. Survival analysis showed the highest five-year survival among adherent CPAP/Auto-CPAP users (95.6%), followed by non-adherent CPAP (95%) and adherent BiPAP users (94.1%). Lower survival was observed in non-adherent BiPAP users (91.7%) and oxygen therapy patients (80.6%). In multivariable analysis, treatment type, older age, congestive heart failure, chronic lung disease, and metastatic cancer were independently associated with increased mortality risk. Conclusions: Five-year survival in patients with obstructive sleep apnea was significantly associated with the treatment modality and adherence level.
1. Introduction
Obstructive sleep apnea (OSA) is a chronic respiratory disorder affecting approximately one billion people worldwide, with an estimated prevalence of 10%, a figure that continues to rise, largely driven by the global increase in obesity [1,2]. It is characterized by recurrent episodes of upper airway obstruction during sleep, leading to sleep fragmentation, intermittent hypoxemia, and daytime sleepiness [3]. In addition to impaired quality of life, OSA is also associated with an increased risk of mortality. Therapeutic management is based on positive airway pressure devices, selected surgical interventions, and lifestyle changes, with continuous positive airway pressure (CPAP) being the most commonly used treatment [4].
In the current literature, most randomized controlled trials have evaluated CPAP versus placebo, sham CPAP, or educational interventions, with follow-up periods ranging from six months to five years. While these studies have shown improvements in parameters such as the apnea–hypopnea index (AHI) and daytime sleepiness, assessment of their impact on mortality and other clinical outcomes remains limited. Additionally, there is notable methodological heterogeneity and a lack of direct comparative studies among different therapeutic modalities, such as CPAP, bilevel positive airway pressure (BiPAP), and oxygen therapy [5,6]. Although CPAP has shown efficacy in patients without respiratory comorbidities, BiPAP is usually reserved for patients with hypoventilation or CPAP intolerance, with no evidence of superiority in isolated OSA [7]. Oxygen therapy improves nocturnal saturation but does not reduce AHI or sleepiness [8]. Despite its widespread use, current studies do not systematically integrate long-term comparisons between these strategies, nor do they adequately account for key clinical factors such as therapy adherence [9].
Low adherence to positive airway pressure therapy remains one of the main barriers to achieving effective control of OSA. Adherence is defined as device use ≥4 h per night on at least 70% of days; however, only 50–60% of patients reach this minimum threshold in the long term [10,11]. Despite their importance, few studies have comprehensively compared different therapeutic modalities while simultaneously considering adherence and survival. In this context, the objective of this study was to evaluate the 5-year survival of patients with OSA treated with CPAP, BIPAP, or oxygen therapy.
2. Materials and Methods
A retrospective cohort study with survival analysis was conducted in subjects with OSA who were followed at a tertiary-level institution in Colombia between January 2005 and December 2021.
2.1. Eligibility Criteria
Subjects included were adults over 18 years old with a diagnosis of OSA, defined by an apnea–hypopnea index (AHI) greater than 5 events per hour of sleep, confirmed by polysomnography (PSG) following the criteria of the American Academy of Sleep Medicine (AASM) [12]. Eligible patients presented symptoms such as chronic snoring, excessive daytime sleepiness, persistent fatigue, and sleep disturbances. Exclusion criteria included other sleep disorders or medical conditions with similar symptoms, patients without follow-up survival data, incomplete AHI information, and those without treatment data.
2.2. Variables
Data were collected on demographic characteristics, comorbidities, vital signs, physical examination, evolution of clinical symptoms at admission, and type of treatment (CPAP, BiPAP, Oxygen). Adherence was defined as device use ≥4 h per night on at least 70% of days; data were obtained from device downloads longitudinally over time. The outcome variable was the 5-year overall survival.
To reduce transcription bias, data were verified by at least two members of the research team directly from the electronic medical records, and personnel collecting the information were trained for this task.
2.3. Sample Size
The sample size was calculated using the method described by Ahnn and Anderson [13], based on the log-rank test to compare survival curves. Previous data from a study by Pépin et al. [14] were used, where the mortality was 2.3% in patients with CPAP and 3.6% in those who discontinued CPAP therapy, with a sample size ratio of 3:1. Assuming a 95% confidence level, 90% power, and an estimated 10% loss, a minimum of 3001 subjects were determined.
2.4. Data Analysis
Data were extracted directly from electronic medical records, thoroughly reviewed, and imported into the Research Electronic Data Capture (REDCap) system. They were then exported to Excel for final analysis using Stata 14 software. Qualitative variables were summarized by count and percentage; quantitative variables were expressed as mean and standard deviation if normally distributed, or median and interquartile range if not. Normality was assessed using the Kolmogorov–Smirnov test. For independent sample comparisons, the two-sample t-test with Welch correction or the Mann–Whitney U test was used as appropriate.
Survival analysis was conducted using the Kaplan–Meier method to estimate the survival curves for patients with OSA under different therapies. Differences between the curves were evaluated using the log-rank test. Multivariate analysis was performed using Cox proportional hazards regression to identify potential confounders for 5-year mortality, adjusting for relevant demographic and clinical variables with corresponding hazard ratios (HRs) and 95% confidence intervals. Statistical significance was set at p < 0.05.
3. Results
3.1. General Characteristics of the Population
A total of 3039 patients with obstructive sleep apnea were included (Figure 1), with a mean age of 59.6 years (SD ± 13.93) and a predominance of males (59.8%). The five-year mortality rate was 5.8%, occurring more frequently in individuals aged >65 years (75.6% vs. 34.7%; p < 0.001). The most common symptoms were snoring (53.2%), daytime hypersomnolence (43.4%), and insomnia (29.3%) (Table 1).
3.2. Medical History and Comorbidities of the Population
The most common comorbidities were hypertension (61.7%), smoking (40.3%), and diabetes mellitus (21.7%), all of which were more prevalent among the deceased patients (p < 0.001). Higher rates of cardiovascular disease, dementia (19.3% vs. 4.1%; p < 0.001), chronic lung disease (60.2% vs. 20.4%; p < 0.001), and connective tissue disease (13.1% vs. 6.7%; p = 0.001) were also observed in this group. Uncomplicated and complicated diabetes, renal failure, and neurological sequelae from stroke were more frequent among deceased patients (p < 0.001). Cancer (24%, p < 0.001) and metastasis (10.5% vs. 0.7%, p < 0.001) were also associated with higher mortality rates (Table 2).
3.3. Treatment Adherence
Regarding adherence to CPAP therapy, deceased patients had a lower proportion of days of use (60.2 vs. 69.9%, p < 0.001) and a lower overall adherence rate (66.9% vs. 78%; p < 0.001). The proportion of days with more than four hours of use was lower among deceased patients, although this difference was not statistically significant (62.1% vs. 69.2%; p = 0.067) (Table 1).
3.4. Survival Analysis
Five-year survival varied significantly (p < 0.001) according to the type of treatment, as illustrated by the Kaplan–Meier survival curve (Figure 2). Patients adherent to CPAP or Auto-CPAP had the highest survival rate (95.6%), followed by non-adherent CPAP users (95%), and adherent BIPAP users (94.1%). In contrast, survival was lower among nonadherent BIPAP users (91.7%) and those using supplemental oxygen (80.6%) (Table 3).
In multivariable Cox regression analysis, treatment type was independently associated with mortality risk (HR, 1.20; 95% CI, 1.03–1.40; p = 0.018). Other variables associated with increased mortality included age (HR: 1.05 per additional year; 95% CI: 1.03–1.07; p < 0.001), congestive heart failure (HR: 2.20; 95% CI: 1.46–3.30; p < 0.001), chronic lung disease (HR: 1.90; 95% CI: 1.27–2.86; p = 0.002), and metastatic cancer (HR: 5.18; 95% CI: 2.58–10.40; p < 0.001) (Table 4).
4. Discussion
In the present study, five-year survival in patients with obstructive sleep apnea (OSA) Treatment modality and adherence were associated with differences in 5-year survival (HR: 1.20; 95% CI: 1.03 to 1.40; p = 0.018). Patients who adhered to CPAP or Auto-CPAP had the highest survival rates (95.6%), followed by those who did not meet the adherence criteria and adherent BIPAP users. Lower survival rates were observed among non-adherent BIPAP users and those who used oxygen (80.6%). Deceased patients were older and had a higher prevalence of comorbidities, such as hypertension, diabetes, chronic lung disease, heart failure, and metastatic cancer. Additionally, they showed lower overall adherence to CPAP therapy and a lower proportion of days of effective use.
The analysis of outcomes according to different therapeutic strategies showed that both treatment modality and specific comorbidities are associated with variations in mid-term survival in patients with OSA. As a local Colombian study, these findings provide valuable insights into the relevance of these associations within our specific healthcare and population context. Patients with sustained adherence to CPAP or auto-CPAP showed higher survival rates, a finding related to the reduction in the apnea–hypopnea index and the frequency of nocturnal desaturations, parameters linked to a lower incidence of cardiovascular events, and mortality [5,15]. In the subgroup treated with BIPAP, the survival was slightly lower than that with CPAP, regardless of adherence. This may be due to the fact that BIPAP is usually indicated in patients with hypoventilation or more advanced chronic respiratory diseases, who more frequently present with heart failure, chronic lung disease, and renal failure, translating into a higher comorbidity burden and less favorable baseline prognosis compared to the CPAP group [6]. The exclusive use of supplemental oxygen was associated with lower survival, consistent with evidence indicating that this strategy does not directly address airway obstruction or modify exposure to intermittent hypoxemia, which are factors influencing the clinical course of OSA [8].
Regarding adherence, deceased patients showed a lower proportion of CPAP use days and a significantly lower adherence rate than the rest of the cohort. Although the difference in the percentage of nights with effective use greater than four hours did not reach statistical significance, the observed trend aligns with previous data, suggesting a direct relationship between therapeutic compliance and reduction in adverse events [16]. Furthermore, the presence of comorbidities such as congestive heart failure, chronic obstructive pulmonary disease (COPD), renal failure, and metastatic cancer among deceased patients underscores the importance of considering the overall clinical profile when selecting the treatment modality. Tailored strategies aimed at optimizing adherence should be prioritized, as recommended by the American Academy of Sleep Medicine guidelines [5].
In terms of population characteristics, a predominance of male patients and a mean age of approximately 60 years were observed, which is consistent with the results of previous studies [2,17]. Mortality was higher among patients over 65 years of age, who also had a lower body mass index and higher residual apnea–hypopnea index, suggesting reduced physiological reserve. Although some studies have proposed a greater impact of OSA in younger adults, this relationship has not yet been clearly established [18]. In the Colombian context, altitude conditions could exacerbate intermittent hypoxemia, promote pulmonary vascular remodeling, and reduce physiological reserves. As noted by Brito et al., chronic or intermittent hypobaric hypoxia, typical of certain South American regions, may intensify hypoxic stress and worsen outcomes in individuals with lower adaptive capacities, such as older adults [19]. Deceased patients also exhibited lower frequencies of typical symptoms, such as snoring and lower CPAP adherence, which in older adults may reflect lower disease perception and delayed access to treatment.
Comorbidities play a key role in patient survival. Cardiovascular, respiratory, and oncologic conditions are more common among deceased patients with congestive heart failure, COPD, complicated diabetes, and metastatic cancer, which are factors associated with a worse prognosis [20,21,22]. These conditions not only reflect greater systemic deterioration but may also amplify the effects of OSA. In this context, OSA acts as a destabilizing factor, and its management should comprehensively consider the patient’s clinical profile to optimize both adherence and clinical outcomes [23,24].
The limitations of this study include its observational design and the use of clinical records as the primary source of information, which may have led to omissions or variability in data quality. Although standardized protocols were applied to minimize information bias, its complete elimination cannot be guaranteed. Furthermore, as this was a single-center study, the generalizability of the findings to other populations may be limited. Another important limitation is the potential influence of unmeasured confounders, such as differences in socioeconomic status, medication use, or treatment duration, which could have affected the observed associations. Therefore, these results should be interpreted with caution and further validated in larger, multicenter studies. Nonetheless, the adequate sample size and the consistency of the results support the internal validity of the analysis. Future multicenter research could provide a more comprehensive understanding of the impact of adherence and comorbidities on the survival of patients with OSA.
5. Conclusions
Five-year survival in patients with obstructive sleep apnea was significantly associated with the treatment modality and adherence level. The presence of severe comorbidities and lower CPAP adherence were related to higher mortality.
Author Contributions
Conceptualization, J.S.H.P. and A.R.B.; methodology, E.A.T.Q. and J.D.A.O.; software, C.F.C.M.; validation, A.R.B., V.L.F. and L.M.L.N.; formal analysis, E.A.T.Q. and M.C.V.E.; investigation, I.L.G., A.M.V., P.S.M.S., C.K.F.G. and G.D.R.; resources, A.R.B. and M.C.V.E.; data curation, G.D.R. and A.J.R.N.; writing—original draft preparation, J.S.H.P., V.L.F., and A.J.R.N.; writing—review and editing, A.R.B., E.A.T.Q. and J.D.C.C.; visualization, J.D.C.C. and I.L.G.; supervision, A.R.B. and E.A.T.Q.; project administration, A.R.B.; funding acquisition, A.R.B. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by Universidad de la Sabana Grant (MEDESP-98-2025).
Institutional Review Board Statement
This study was reviewed and approved by the Academic Research Ethics Committee of Clínica Universidad de La Sabana (Act No. 44, 7 December 2021; Project Code 20211203). In accordance with Colombian Resolution 8430 of 1993 [25], it was classified as no risk. All patient privacy and confidentiality policies were strictly observed, and the project was approved on bioethical and methodological grounds.
Informed Consent Statement
Patient consent was waived because this was a retrospective observational cohort study. The study protocol was reviewed and approved by the institutional ethics committee.
Data Availability Statement
We confirm that the dataset underlying this study is held and managed by the Clinical Medicine Applied Research Group (Code: COL0084256), affiliated with the Universidad de La Sabana. The extraction, use, and management of these data were explicitly authorized by the institutional Research Ethics Committee, which approved the study protocol and designated this research group as the responsible entity for data handling and custody. The group is committed to ensuring secure and confidential data management and evaluating any external data access requests in accordance with institutional, legal, and ethical standards. More information about the group can be found on the official MinCiencias GRUPLAC platform (https://scienti.minciencias.gov.co/gruplac/jsp/visualiza/visualizagr.jsp?nro=00000000007713 (accessed on 10 September 2025)). At present, the group’s director is Alirio Rodrigo Bastidas Goyes, who may be contacted at alirio.bastidas@unisabana.edu.co for data access inquiries. In case of any changes in leadership or contact information, the GRUPLAC page will be updated to ensure persistent accessibility.
Acknowledgments
The authors are most thankful for the Universidad de La Sabana.
Conflicts of Interest
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Abbreviations
The following abbreviations are used in this manuscript:
| OSA | Obstructive Sleep Apnea |
| CPAP | Continuous Positive Airway Pressure |
| Auto-CPAP | Automatic Continuous Positive Airway Pressure |
| BiPAP | Bilevel Positive Airway Pressure |
| AHI | Apnea–Hypopnea Index |
| PSG | Polysomnography |
| AASM | American Academy of Sleep Medicine |
| HR | Hazard Ratio |
| CI | Confidence Interval |
| HIV | Human Immunodeficiency Virus |
| AIDS | Acquired Immune Deficiency Syndrome |
| Sd | Standard Deviation |
| M | Median |
| IQR | Interquartile Range |
| BMI | Body Mass Index |
| COPD | Chronic Obstructive Pulmonary Disease |
| REDCap | Research Electronic Data Capture |
References
- Lyons, M.M.; Bhatt, N.Y.; Pack, A.I.; Magalang, U.J. Global burden of sleep-disordered breathing and its implications. Respirology 2020, 25, 690–702. [Google Scholar] [CrossRef]
- Senaratna, C.V.; Perret, J.L.; Lodge, C.J.; Lowe, A.J.; Campbell, B.E.; Matheson, M.C.; Hamilton, G.S.; Dharmage, S.C. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med. Rev. 2017, 34, 70–81. [Google Scholar] [CrossRef]
- McNicholas, W.T.; Pevernagie, D. Obstructive sleep apnea: Transition from pathophysiology to an integrative disease model. J. Sleep Res. 2022, 31, e13616. [Google Scholar] [CrossRef]
- Chang, H.P.; Chen, Y.F.; Du, J.K. Obstructive sleep apnea treatment in adults. Kaohsiung J. Med. Sci. 2020, 36, 7–12. [Google Scholar] [CrossRef] [PubMed]
- Patil, S.P.; Ayappa, I.A.; Caples, S.M.; John Kimoff, R.; Patel, S.R.; Harrod, C.G. Treatment of adult obstructive sleep apnea with positive airway pressure: An American academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. 2019, 15, 335–343. [Google Scholar] [CrossRef] [PubMed]
- McEvoy, R.D.; Antic, N.A.; Heeley, E.; Luo, Y.; Ou, Q.; Zhang, X.; Mediano, O.; Chen, R.; Drager, L.F.; Liu, Z.; et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N. Engl. J. Med. 2016, 375, 919–931. [Google Scholar] [CrossRef]
- Zheng, Y.; Yee, B.J.; Wong, K.; Grunstein, R.; Piper, A. A pilot randomized trial comparing CPAP vs. bilevel PAP spontaneous mode in the treatment of hypoventilation disorder in patients with obesity and obstructive airway disease. J. Clin. Sleep Med. 2022, 18, 99–107. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Luo, J.; Wang, Y. Comparing the effects of supplemental oxygen therapy and continuous positive airway pressure on patients with obstructive sleep apnea: A meta-analysis of randomized controlled trials. Sleep Breath. 2021, 25, 2231–2240. [Google Scholar] [CrossRef]
- Bocoum, A.M.; Bailly, S.; Joyeux-Faure, M.; Baillieul, S.; Arbib, F.; Kang, C.L.; Ngo, V.; Boutouyrie, P.; Tamisier, R.; Pépin, J.L. Long-term outcomes of CPAP-treated sleep apnea patients: Impact of blood-pressure responses after CPAP initiation and of treatment adherence. Sleep Med. 2023, 109, 25–31. [Google Scholar] [CrossRef]
- Rotenberg, B.W.; Murariu, D.; Pang, K.P. Trends in CPAP adherence over twenty years of data collection: A flattened curve. J. Otolaryngol.-Head Neck Surg. 2016, 45, 43. [Google Scholar] [CrossRef]
- Weaver, T.E.; Grunstein, R.R. Adherence to continuous positive airway pressure therapy: The challenge to effective treatment. Proc. Am. Thorac. Soc. 2008, 5, 173–178. [Google Scholar] [CrossRef]
- Kapur, V.K.; Auckley, D.H.; Chowdhuri, S.; Kuhlmann, D.C.; Mehra, R.; Ramar, K.; Harrod, C.G. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. Am. Acad. Sleep Med. 2017, 13, 479–504. [Google Scholar] [CrossRef] [PubMed]
- Anderson, S.J. Sample size determination for comparing more than two survival distributions. Stat. Med. 1995, 14, 2273–2282. [Google Scholar] [CrossRef] [PubMed]
- Pépin, J.L.; Bailly, S.; Rinder, P.; Adler, D.; Benjafield, A.V.; Lavergne, F.; Josseran, A.; Sinel-Boucher, P.; Tamisier, R.; Cistulli, P.A.; et al. Relationship Between CPAP Termination and All-Cause Mortality: A French Nationwide Database Analysis. Chest 2022, 61, 1657–1665. [Google Scholar] [CrossRef]
- Tuta-Quintero, E.; Bastidas, A.R.; Faizal-Gómez, K.; Torres-Riveros, S.G.; Rodríguez-Barajas, D.A.; Guezguan, J.A.; Muñoz, L.D.; Rojas, A.C.; Calderón, K.H.; Velasco, N.V.A.; et al. Survival and Risk Factors Associated with Mortality in Patients with Sleep Apnoea in Colombia: A Retrospective Cohort Study. Nat. Sci. Sleep 2024, 16, 1601–1610. [Google Scholar] [CrossRef] [PubMed]
- Weaver, T.E.; Maislin, G.; Dinges, D.F.; Bloxham, T.; George, C.F.; Greenberg, H.; Kader, G.; Mahowald, M.; Younger, J.; Pack, A.I. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007, 30, 711–719. [Google Scholar] [CrossRef]
- Punjabi, N.M. The epidemiology of adult obstructive sleep apnea. Proc. Am. Thorac. Soc. 2008, 5, 136–143. [Google Scholar] [CrossRef]
- Osorio, R.S.; Martínez-García, M.Á.; Rapoport, D.M. Sleep apnoea in the elderly: A great challenge for the future. Eur. Respir. J. 2022, 59, 2101649. [Google Scholar] [CrossRef]
- Brito, J.; Siques, P.; Pena, E. Long-term chronic intermittent hypoxia: A particular form of chronic high-altitude pulmonary hypertension. Pulm. Circ. 2020, 10, 5–12. [Google Scholar] [CrossRef]
- Zhou, D.; Xi, B.; Zhao, M.; Wang, L.; Veeranki, S.P. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III Linked Mortality Study. Sci. Rep. 2018, 8, 9418. [Google Scholar] [CrossRef]
- Campbell, P.T.; Jacobs, E.J.; Newton, C.C.; Gapstur, S.M.; Patel, A.V. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012, 35, 1835–1844. [Google Scholar] [CrossRef] [PubMed]
- Hwang, J.; Jo, S.; Cheon, E.; Kang, H.; Cho, S.I. Dose-response risks of all-cause, cancer, and cardiovascular disease mortality according to sex-specific cigarette smoking pack-year quantiles. Tob. Induc. Dis. 2024, 22. [Google Scholar] [CrossRef]
- Liu, W.; Zhang, L.; Liao, W.; Liu, H.; Liang, W.; Yan, J.; Huang, Y.; Jiang, T.; Wang, Q.; Zhang, C. Unveiling the molecular and cellular links between obstructive sleep apnea-hypopnea syndrome and vascular aging. Chin. Med. J. 2025, 138, 155–171. [Google Scholar] [CrossRef]
- Mao, Z.; Zheng, P.; Zhu, X.; Wang, L.; Zhang, F.; Liu, H.; Zhou, L.; Liu, W. Obstructive sleep apnea hypopnea syndrome and vascular lesions: An update on what we currently know. Sleep Med. 2024, 119, 296–311. [Google Scholar] [CrossRef] [PubMed]
- Mateus, J.C.; Varela, M.T.; Caicedo, D.M.; Arias, N.L.; Jaramillo, C.D.; Morales, L.C.; Palma, G.I. ¿Responde la Resolución 8430 de 1993 a las necesidades actuales de la ética de la investigación en salud con seres humanos en Colombia? Biomedica 2019, 39, 448–463. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Flowchart of study.
Figure 2.
Survival curve Kaplan–Meier by treatment type.
Table 1.
General characteristics of the population.
| Total Population n = 3039 | Alive n = 2863 | Deceased n = 176 | p-Value | |
|---|---|---|---|---|
| Age (years) x (sd) | 59.6 (13.93) | 58.8 (13.63) | 72.2 (12.72) | <0.001 |
| >65 years n (%) | 1126 (37.1) | 993 (34.7) | 133 (75.6) | <0.001 |
| Male n (%) | 1818 (59.8) | 1712 (59.8) | 106 (60.2) | 0.910 |
| Anthropometric measurements | ||||
| Weight Kg x (sd) | 80 (15.67) | 80.3 (15.64) | 75.6 (15.62) | <0.001 |
| Height Mt’s x (sd) | 1.63 (0.1) | 1.64 (0.1) | 1.61 (0.09) | <0.001 |
| BMI Kg/m2 x (sd) | 30 (5.34) | 30 (5.28) | 29 (6.14) | 0.039 |
| Symptoms | ||||
| Daytime hypersomnia n (%) | 1126 (43.4) | 1068 (43.8) | 58 (37.2) | 0.104 |
| Insomnia n (%) | 751 (29.3) | 709 (29.5) | 42 (27.1) | 0.530 |
| Snoring n (%) | 1384 (53.2) | 1317 (53.9) | 67 (42.9) | 0.008 |
| Tired-fatigued n (%) | 765 (29.8) | 722 (30) | 43 (27.6) | 0.522 |
| Observed_Apneas n (%) | 1063 (42.1) | 998 (42.1) | 65 (42.2) | 0.974 |
| Neck diameter x (sd) | 41.3 (5.14) | 41.3 (5.17) | 40.9 (4.35) | 0.194 |
| CPAP Adherence | ||||
| Days of CPAP use x (sd) | 69.5 (20.13) | 69.9 (19.84) | 60.2 (26.09) | <0.001 |
| CPAP Adherence % x (sd) | 77.6 (21.82) | 78 (21.47) | 66.9 (28.99) | <0.001 |
| Days of use greater than 4 h x (sd) | 68.6 (29.92) | 69.2 (28.09) | 62.1 (50.79) | 0.067 |
| Average hours of CPAP use M (IQR) | 5.2 (4–6.53) | 5.5 (3.7–7.58) | 5.2 (4–6.5) | 0.992 |
| Residual AHI M (IQR) | 8.9 (3–27.8) | 15 (4.05–29.3) | 8.5 (3–27.6) | 0.110 |
Sd: standard deviation; M: median; IQR: interquartile range; BMI: body mass index; CPAP: continuous positive airway pressure.
Table 2.
Medical history of the population.
| Total Population n = 3039 | Alive n = 2863 | Deceased n = 176 | p-Value | |
|---|---|---|---|---|
| Medical History n (%) | ||||
| Smoking | 1222 (40.3) | 1123 (39.3) | 99 (56.3) | <0.001 |
| Hypertension | 1875 (61.7) | 1728 (60.4) | 147 (83.5) | <0.001 |
| Depression | 298 (9.8) | 276 (9.6) | 22 (12.5) | 0.217 |
| Alcohol use | 170 (5.6) | 147 (5.1) | 23 (13.1) | <0.001 |
| Myocardial infarction | 339 (11.2) | 301 (10.5) | 38 (21.6) | <0.001 |
| Atrial fibrillation | 218 (7.2) | 176 (6.2) | 42 (23.9) | <0.001 |
| Congestive heart failure | 355 (11.7) | 286 (10) | 69 (39.2) | <0.001 |
| Peripheral vascular disease | 190 (6.3) | 169 (5.9) | 21 (11.9) | 0.001 |
| Cerebrovascular disease | 229 (7.5) | 194 (6.8) | 35 (19.9) | <0.001 |
| Dementia | 151 (5) | 117 (4.1) | 34 (19.3) | <0.001 |
| Chronic lung disease | 689 (22.7) | 583 (20.4) | 106 (60.2) | <0.001 |
| Connective tissue disease | 214 (7) | 191 (6.7) | 23 (13.1) | 0.001 |
| Peptic ulcer | 354 (11.7) | 330 (11.5) | 24 (13.6) | 0.399 |
| Non-malignant liver disease | 265 (8.7) | 249 (8.7) | 16 (9.1) | 0.900 |
| Liver disease | 67 (2.2) | 60 (2.1) | 7 (4) | 0.099 |
| Diabetes | 659 (21.7) | 586 (20.5) | 73 (41.5) | <0.001 |
| Diabetes with end-organ damage | 89 (3.1) | 73 (2.7) | 16 (9.4) | <0.001 |
| Hemiplegia/stroke sequelae | 88 (3.1) | 73 (2.7) | 15 (8.8) | <0.001 |
| Renal failure | 216 (7.1) | 177 (6.2) | 39 (22.2) | <0.001 |
| Leukemia | 8 (0.3) | 7 (0.2) | 1 (0.6) | 0.416 |
| Lymphoma | 14 (0.5) | 12 (0.4) | 2 (1.1) | 0.173 |
| Other types of cancer | 263 (8.7) | 221 (7.7) | 42 (24) | <0.001 |
| Metastasis | 37 (1.3) | 19 (0.7) | 18 (10.5) | <0.001 |
| HIV/AIDS | 5 (0.2) | 4 (0.1) | 1 (0.6) | 0.174 |
| Traffic accidents | 119 (3.9) | 107 (3.7) | 12 (6.8) | 0.041 |
HIV: human immunodeficiency virus; AIDS: acquired immune deficiency syndrome.
Table 3.
Type of treatment.
| Total Population | Alive | Deceased | p-Value | |
|---|---|---|---|---|
| Adherent CPAP or Auto-CPAP n (%) | 2454 | 2345 (95.6) | 109 (4.4) | <0.001 |
| Non-adherent CPAP or Auto-CPAP n (%) | 140 | 133 (95) | 7 (5) | |
| Adherent BiPAP n (%) | 186 | 175 (94.1) | 11 (5.9) | |
| Non-Adherent BiPAP n (%) | 12 | 11 (91.7) | 1 (8.3) | |
| Oxygen Use n (%) | 247 | 199 (80.6) | 48 (19.4) |
CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure.
Table 4.
Cox regression: independent characteristics associated with mortality.
| Hazard Ratio | 95% Confidence Interval (CI) | p-Value | ||
|---|---|---|---|---|
| Positive pressure treatment | 1.204 | 1.032 | 1.404 | 0.018 |
| Age (years) | 1.051 | 1.032 | 1.070 | <0.001 |
| Sex | 1.120 | 0.761 | 1.647 | 0.565 |
| Body mass index | 0.981 | 0.946 | 1.017 | 0.289 |
| Smoking history | 0.990 | 0.686 | 1.427 | 0.955 |
| Hypertension | 1.114 | 0.657 | 1.889 | 0.690 |
| Alcohol use | 1.423 | 0.825 | 2.456 | 0.205 |
| Myocardial infarction | 1.035 | 0.684 | 1.566 | 0.871 |
| Atrial fibrillation | 1.208 | 0.783 | 1.863 | 0.392 |
| Congestive heart failure | 2.198 | 1.463 | 3.302 | <0.001 |
| Peripheral vascular disease | 0.984 | 0.590 | 1.639 | 0.950 |
| Cerebrovascular disease | 1.125 | 0.703 | 1.801 | 0.623 |
| Dementia | 1.265 | 0.780 | 2.052 | 0.340 |
| Chronic lung disease | 1.904 | 1.269 | 2.856 | 0.002 |
| Connective tissue disease | 1.597 | 0.950 | 2.684 | 0.077 |
| Diabetes | 1.370 | 0.942 | 1.993 | 0.099 |
| Chronic kidney disease | 1.425 | 0.934 | 2.173 | 0.100 |
| Other cancer | 1.097 | 0.676 | 1.778 | 0.708 |
| Metastatic cancer | 5.181 | 2.582 | 10.396 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Hernández Puentes, J.S.; Bastidas, A.R.; Tuta Quintero, E.A.; Acosta Otero, J.D.; Leyton Franco, V.; Castro Córdoba, J.D.; López Nuñez, L.M.; Lenhardt Guaqueta, I.; Mora Vega, A.; Martínez Sáenz, P.S.; et al. Positive Airway Pressure Therapies and Oxygen Therapy in Obstructive Sleep Apnea (OSA): 5-Year Survival. J. Clin. Med. 2025, 14, 8647. https://doi.org/10.3390/jcm14248647
AMA Style
Hernández Puentes JS, Bastidas AR, Tuta Quintero EA, Acosta Otero JD, Leyton Franco V, Castro Córdoba JD, López Nuñez LM, Lenhardt Guaqueta I, Mora Vega A, Martínez Sáenz PS, et al. Positive Airway Pressure Therapies and Oxygen Therapy in Obstructive Sleep Apnea (OSA): 5-Year Survival. Journal of Clinical Medicine. 2025; 14(24):8647. https://doi.org/10.3390/jcm14248647
Chicago/Turabian StyleHernández Puentes, Juan Sebastian, Alirio Rodrigo Bastidas, Eduardo Andres Tuta Quintero, Juan David Acosta Otero, Valeria Leyton Franco, Juan Diego Castro Córdoba, Lina María López Nuñez, Isabella Lenhardt Guaqueta, Alejandra Mora Vega, Paola Stefanny Martínez Sáenz, and et al. 2025. "Positive Airway Pressure Therapies and Oxygen Therapy in Obstructive Sleep Apnea (OSA): 5-Year Survival" Journal of Clinical Medicine 14, no. 24: 8647. https://doi.org/10.3390/jcm14248647
APA StyleHernández Puentes, J. S., Bastidas, A. R., Tuta Quintero, E. A., Acosta Otero, J. D., Leyton Franco, V., Castro Córdoba, J. D., López Nuñez, L. M., Lenhardt Guaqueta, I., Mora Vega, A., Martínez Sáenz, P. S., Faizal Gomez, C. K., Vaca Espinosa, M. C., Cardona Molina, C. F., Diaz Romero, G., & Rubio Noel, A. J. (2025). Positive Airway Pressure Therapies and Oxygen Therapy in Obstructive Sleep Apnea (OSA): 5-Year Survival. Journal of Clinical Medicine, 14(24), 8647. https://doi.org/10.3390/jcm14248647
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
